FY2025 · ended Dec 31, 2025 · Revenue $606.42M, +66.7% YoY · Filed Feb 19, 2026
Insmed Inc (INSM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $606.4 million and a net loss of $1.3 billion. Free cash flow was -$967.6 million. As of Sep 30, 2026 it held $1.1 billion in cash and investments and $594.9 million in total debt.
Revenue (TTM)
$1.52B
+240.0% vs year-ago TTM
Net income (TTM)
$-605.61M
+48.8% vs year-ago TTM
Operating cash flow (TTM)
$-595.62M
+32.6% vs year-ago TTM
Free cash flow (TTM)
$-627.58M
+30.7% vs year-ago TTM
EPS (TTM)
$-2.80
+55.0% vs year-ago TTM
Dividend per share
None
Shares outstanding
215.55M
+19.1% vs prior year
Net cash
$551.69M
as of Sep 30, 2026
Operating margin
-37.1%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- INSM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- VA
- Headquarters
- Bridgewater, NJ
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1104506
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $606.4M | $363.7M | $305.2M | $245.4M | $188.5M |
| Operating income | -$1.2B | -$878.3M | -$709.6M | -$457.3M | -$375.1M |
| Net income | -$1.3B | -$913.8M | -$749.6M | -$481.5M | -$434.7M |
| Diluted EPS | -$6.42 | -$5.57 | -$5.34 | -$3.91 | -$3.88 |
| Operating cash flow | -$935.0M | -$683.9M | -$536.2M | -$400.4M | -$363.3M |
| Free cash flow | -$967.6M | -$705.8M | -$549.5M | -$410.3M | -$370.6M |
| Total assets | $2.3B | $2.0B | $1.3B | $1.7B | $1.2B |
| Total liabilities | $1.5B | $1.7B | $1.7B | $1.6B | $833.0M |
| Stockholders' equity | $739.0M | $285.4M | -$331.9M | $88.0M | $410.5M |
| Cash and investments | $1.4B | $1.4B | $780.4M | $1.1B | $766.8M |
| Total debt | $592.5M | $1.2B | $1.2B | $1.2B | $845.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Oct 29, 2026 | Oct 29, 2026 |
| 10-Q | Quarterly report | Oct 29, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 20, 2026 | Oct 16, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Oct 5, 2026 | Oct 5, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
All 1011 Insmed Inc SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.